Publication | Closed Access

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Hematological MalignancyMedicinePharmacologyCancer Cell BiologyMultiple MyelomaMolecular OncologyPhase 1OncologyRadiation OncologyCancer ResearchIntermittent SchedulesTumor BiologyMyeloid Neoplasia